首页> 美国卫生研究院文献>Journal for Immunotherapy of Cancer >Avelumab (anti–PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial

【2h】

Avelumab (anti–PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial

机译：Avelumab（anti-PD-L1）作为晚期胃癌或胃食管连接癌患者的一线开关维持或二线治疗：JAVELIN实体瘤试验的1b期结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundWe evaluated the antitumor activity and safety of avelumab, a human anti–PD-L1 IgG1 antibody, as first-line switch-maintenance (1 L-mn) or second-line (2 L) treatment in patients with advanced gastric/gastroesophageal cancer (GC/GEJC) previously treated with chemotherapy.

机译：背景我们评估了人抗PD-L1 IgG1抗体avelumab的抗肿瘤活性和安全性，作为晚期胃/胃食管癌患者的一线转换维持（1 L-mn）或二线（2 L）治疗（GC / GEJC）之前接受过化疗。

著录项

期刊名称 Journal for Immunotherapy of Cancer
作者
Hyun Cheol Chung; Hendrik-Tobias Arkenau; Jeeyun Lee; Sun Young Rha; Do-Youn Oh; Lucjan Wyrwicz; Yoon-Koo Kang; Keun-Wook Lee; Jeffrey R. Infante; Sung Sook Lee; Margaret Kemeny; Ulrich Keilholz; Bohuslav Melichar; Alain Mita; Ruth Plummer; Denis Smith; Arnold B. Gelb; Huiling Xiong; Janet Hong; Vikram Chand; Howard Safran;
展开▼
作者单位

展开▼
年(卷),期 2019(7),-1
年度 2019
页码 30
总页数 10
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词
Avelumab Metastatic Gastric Esophagogastric junction Adenocarcinoma Maintenance;

机译：Avelumab;转移性;胃;食管胃交界处;腺癌;维持;

相似文献

外文文献
中文文献
专利

1. Avelumab (anti–PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial [J] . Hyun Cheol Chung, Hendrik-Tobias Arkenau, Jeeyun Lee, Journal for ImmunoTherapy of Cancer . 2019,第1期

机译：Avelumab（anti-PD-L1）作为晚期胃或胃食管连接癌患者的一线开关维持或二线治疗：JAVELIN实体瘤试验的1b期结果
2. Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial [J] . Doi Toshihiko, Iwasa Satoru, Muro Kei, Gastric cancer: official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association . 2019,第4期

机译：日本晚期实体肿瘤患者中Avelumab（抗PD-L1）的第1阶段试验，包括胃或胃食管术患者的剂量膨胀：标枪实体瘤JPN试验
3. Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300 [J] . Bang Y. -J., Ruiz E. Yanez, Van Cutsem E., Annals of oncology: official journal of the European Society for Medical Oncology . 2018,第10期

机译：III期，Avelumab的随机试验与医生选择化疗选择为晚期胃或胃食性癌症的第三线治疗：标枪胃300的初步分析
4. Weekly Paclitaxel Therapy as the Second-line Chemotherapy to TS-1 for Advanced/Metastatic Gastric Cancer [C] . M. Fujishima, H. Imamura, H. Furukawa, International Gastric Cancer Congress . 2005

机译：每周紫杉醇治疗作为先进/转移性胃癌的二线化学疗法至TS-1
5. Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy [D] . 鈴木, 裕子 2019

机译：吉西他滨联合顺铂一线化疗对晚期胆道癌患者治疗效果的预测因素
6. Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial [O] . Toshihiko Doi, Satoru Iwasa, Kei Muro, -1

机译：在日本晚期实体瘤患者中进行avelumab（anti-PD-L1）的1期试验包括胃或胃食管连接癌患者的剂量扩大：JAVELIN实体瘤JPN试验
7. Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial [O] . Toshihiko Doi, Satoru Iwasa, Kei Muro, 2018

机译：日本先进实体瘤患者中Avelumab（抗PD-L1）的第1阶段试验，包括胃或胃食管癌患者的剂量扩张：标枪实体瘤JPN试验

Avelumab (anti–PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial

摘要

著录项

相似文献

相关主题

期刊订阅